Mouse Monoclonal FGFR1OP2 Antibody

+ +

•  

   
     Overlay histogram showing U-2OS cells stained with AM8701b(green line).  The cells were fixed with 2% paraformaldehyde (10 min) and then permeabilized with 90% methanol for 10 min.  The cells were then icubated in 2% bovine serum albumin to block non-specific protein-protein interactions followed by the antibody (AM8701b,  1:25 dilution) for 60 min at 37ºC.  The secondary antibody used was Goat-Anti-Mouse IgG, DyLight® 488 Conjugated Highly Cross-Adsorbed(OJ192088) at 1/200 dilution for 40 min at 37ºC.  Isotype control antibody (blue line) was mouse IgG2a (1μg/1x10^6 cells) used under the same conditions.  Acquisition of >10, 000 events was performed.    

FGFR1OP2 (Fibroblast Growth Factor Receptor 1 Oncogene Partner 2), also known as CEP43. is a protein-coding gene located on chromosome 12p11.21. It was initially identified as a fusion partner of FGFR1 in rare myeloproliferative disorders caused by chromosomal translocations, particularly the t(12;8)(p11;p11) rearrangement. The gene encodes a centrosomal protein involved in regulating centrosome integrity, cilia formation, and cell cycle progression. Structurally, FGFR1OP2 contains a leucine zipper domain and coiled-coil motifs, suggesting roles in protein-protein interactions and complex assembly.

Antibodies targeting FGFR1OP2 are primarily used in research to study its expression patterns, subcellular localization, and functional mechanisms. These antibodies enable detection of FGFR1OP2 in techniques like Western blotting, immunofluorescence, and immunohistochemistry. Studies have linked FGFR1OP2 to primary microcephaly and ciliopathies when mutated, as well as cancer progression through centrosome amplification-related genomic instability. Its interaction with centrosomal proteins like CEP250 highlights its importance in mitotic regulation. Researchers utilize FGFR1OP2 antibodies to explore its dual roles in physiological processes and disease contexts, particularly in cancers with FGFR1 rearrangements or centrosome dysfunction. Commercial antibodies are typically validated for specificity using knockout cell lines or siRNA knockdown controls.